Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2200066640Phase 4Not yet recruiting
Phase 4, open-label trial of remimazolam and alfentanil in gynaecological conditions (4 arms), sponsored by Weifang People's Hospital. Primary endpoint: Induction dose of remimazolam. Planned start Dec 2022; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2200066640.